AstraZeneca Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
I'm PortAI, I can summarize articles.
AstraZeneca reported its Q2 2025 earnings with revenues of $14.5 billion, a 12% increase from Q2 2024, exceeding expectations by 2.6%. However, EPS of $1.58 fell short of estimates by 5.4%. Net income rose 27% to $2.45 billion, with a profit margin of 17%. Revenue is projected to grow 5.7% annually over the next three years, slightly above the UK Pharmaceuticals industry's forecast of 5.2%. AstraZeneca's shares have increased by 2.9% over the past week, but the company faces three warning signs that investors should consider.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Simplywall The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments